Diabetes

Basal insulin analogues similar for glucose lowering

(HealthDay)—Basal insulin analogues for type 2 diabetes mellitus (T2DM) do not substantially differ in their glucose-lowering effect, according to a review published online July 10 in the Annals of Internal Medicine.

Diabetes

HbA1c targets should be personalized in type 2 diabetes

(HealthDay)—For non-pregnant adults with type 2 diabetes, hemoglobin A1c (HbA1c) targets should be personalized, according to a Clinical Guidelines Synopsis published in the June 19 issue of the Journal of the American ...

Diabetes

Fat intake influences HbA1c-lowering effect in DPP4i therapy

(HealthDay)—For individuals with type 2 diabetes (T2D), fat intake may contribute to the deterioration of the hemoglobin A1c (HbA1c)-lowering effects in dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy, according to ...

Surgery

Blueprint to reduce wasteful blood transfusions

By analyzing data from randomized clinical trials comparing blood transfusion approaches, Johns Hopkins experts, along with colleagues at Cleveland Clinic and NYU Langone Medical Center, endorse recommendations for blood ...

Cardiology

Risk conferred by T2D modified by HbA1c in heart failure

(HealthDay)—For patients with heart failure, the risks conferred by type 2 diabetes (T2D) can be stratified by glycemic control and drug treatments, according to a study published online Oct. 11 in JACC: Heart Failure.

Diabetes

Researchers call for paradigm shift in type 2 diabetes treatment

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management ...

page 3 from 10